Polymers with time-dependent properties for drug deliver
具有药物递送时间依赖性特性的聚合物
基本信息
- 批准号:6679820
- 负责人:
- 金额:$ 21.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-07-01 至 2008-06-30
- 项目状态:已结题
- 来源:
- 关键词:SCID mouse antineoplastics biomaterial development /preparation biomaterial evaluation biomaterials biotechnology disease /disorder model drug delivery systems drug vehicle high performance liquid chromatography immunocytochemistry infrared spectrometry laboratory rat microcalorimetry nuclear magnetic resonance spectroscopy ovary neoplasms polyacrylamide polymers tissue /cell culture
项目摘要
DESCRIPTION (provided by applicant): The overall goal of this research is to develop a new class of in situ-forrning, injectable, and biodegradable polymeric biomaterials based on time-dependent molar mass and lower critical solution temperature (LCST) properties for localized delivery of an anti-cancer agent, phenstatin. Many current biodegradable, injectable, and in situ-forming biomaterials under development have disadvantages including the use of water miscible organic solvents for delivery, low molecular weight toxic byproducts, reactive chemistries and the need for external light sources (i.e., for photopolymerization). Ideal replacement materials for these applications would be easily injected and form in a timely fashion without detrimental effects to surrounding tissue from temperature increases, toxicity or invasive techniques. Many of these difficulties can be addressed using NIPAAm copolymers with time-dependent molar mass and lower critical solution temperature (LCST) properties. Copolymers of N-isopropylacrylamide (NIPAAm), methacrylic anhydride(MA) and maleic anhydride (MAn) will possess time-dependent LCST properties in an aqueous environment due to the conversion of maleic anhydride side chains to maleic acid and time-dependent molar mass due to conversion of methacrylic anhydride to methacrylic acid, both by hydrolysis. Copolymers of NIPAAm, methacrylic anhydride, and maleic anhydride will be synthesized and be characterized for initial and final LCST, initial and final molar mass, the initial strength of the gel, and degradation time. Drug release profiles will be evaluated from selected materials. The cytotoxicity and biocompatibility of these materials will be assessed using cell proliferation (MTT) and live/dead assays on BALB/c 3T3 cells. Tissue irritation potential of these materials will be evaluated in vitro by macrophage and lymphocyte activation experiments. Finally, a selected material will be injected subcutaneously into Sprague Dawley rats to verify injectability and in situ formation. In vivo compatibility will be assessed using selected histological techniques. In vivo efficacy of phenstatin released from this material will be evaluated using a SCID mouse ovarian cancer model.
描述(由申请人提供):本研究的总体目标是开发一类新的原位形成、可注射和可生物降解的聚合物生物材料,其基于时间依赖性摩尔质量和低临界溶解温度(LCST)特性,用于局部递送抗癌剂芬他汀。许多目前正在开发的可生物降解、可注射和原位形成的生物材料具有缺点,包括使用水混溶性有机溶剂进行递送、低分子量有毒副产物、反应性化学和需要外部光源(即,用于光聚合)。用于这些应用的理想替代材料将容易地注射并及时形成,而不会因温度升高、毒性或侵入性技术而对周围组织产生有害影响。这些困难中的许多可以使用具有时间依赖性摩尔质量和较低临界溶解温度(LCST)性质的NIPAAm共聚物来解决。N-异丙基丙烯酰胺(NIPAAm)、甲基丙烯酸酐(MA)和马来酸酐(MAn)的共聚物在水性环境中由于马来酸酐侧链转化为马来酸而具有时间依赖性LCST性质,并且由于甲基丙烯酸酐转化为甲基丙烯酸而具有时间依赖性摩尔质量,两者均通过水解。将合成NIPAAm、甲基丙烯酸酐和马来酸酐的共聚物,并表征初始和最终LCST、初始和最终摩尔质量、凝胶的初始强度和降解时间。将评价选定材料的药物释放曲线。将使用BALB/c 3 T3细胞的细胞增殖(MTT)和活/死试验评估这些材料的细胞毒性和生物相容性。将通过巨噬细胞和淋巴细胞活化实验在体外评价这些材料的组织刺激潜力。最后,将选定的材料皮下注射到Sprague道利大鼠中,以验证可注射性和原位形成。将使用选定的组织学技术评估体内相容性。将使用SCID小鼠卵巢癌模型评价从该材料释放的芬他汀的体内功效。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BRENT L VERNON其他文献
BRENT L VERNON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BRENT L VERNON', 18)}}的其他基金
Surface-covering gels for broad-spectrum antimicrobial protection following open
表面覆盖凝胶可在开瓶后提供广谱抗菌保护
- 批准号:
8647241 - 财政年份:2014
- 资助金额:
$ 21.94万 - 项目类别:
Antimicrobial-releasing gels for preventing infection in total joint arthroplasty
用于预防全关节置换术中感染的抗菌释放凝胶
- 批准号:
8453783 - 财政年份:2013
- 资助金额:
$ 21.94万 - 项目类别:
Polymers with time-dependent properties for drug deliver
具有药物递送时间依赖性特性的聚合物
- 批准号:
7087679 - 财政年份:2003
- 资助金额:
$ 21.94万 - 项目类别:
Polymers with time-dependent properties for drug deliver
具有药物递送时间依赖性特性的聚合物
- 批准号:
7252706 - 财政年份:2003
- 资助金额:
$ 21.94万 - 项目类别:
Polymers with time-dependent properties for drug deliver
具有药物递送时间依赖性特性的聚合物
- 批准号:
6768673 - 财政年份:2003
- 资助金额:
$ 21.94万 - 项目类别:
Polymers with time-dependent properties for drug deliver
具有药物递送时间依赖性特性的聚合物
- 批准号:
6909835 - 财政年份:2003
- 资助金额:
$ 21.94万 - 项目类别:
相似海外基金
The analysis of proteinuria caused by antineoplastics and the preventative effects with antihypertensive medications using the Japanese medical database
利用日本医学数据库分析抗肿瘤药物引起的蛋白尿及抗高血压药物的预防效果
- 批准号:
21K17258 - 财政年份:2021
- 资助金额:
$ 21.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Expediting Drug Development by Profiling Novel Antineoplastics by Mass Spectrometry-based Biomarker Profiling
通过基于质谱的生物标志物分析来分析新型抗肿瘤药物,加速药物开发
- 批准号:
499958-2016 - 财政年份:2016
- 资助金额:
$ 21.94万 - 项目类别:
Engage Grants Program
Combinatorial Peptidomimetics as Antineoplastics
作为抗肿瘤药的组合肽模拟物
- 批准号:
6623455 - 财政年份:2002
- 资助金额:
$ 21.94万 - 项目类别:
Combinatorial Peptidomimetics as Antineoplastics
作为抗肿瘤药的组合肽模拟物
- 批准号:
6465958 - 财政年份:2002
- 资助金额:
$ 21.94万 - 项目类别:
Novel Nanoparticle Delivery System for Antineoplastics
新型抗肿瘤纳米颗粒输送系统
- 批准号:
6483914 - 财政年份:2002
- 资助金额:
$ 21.94万 - 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
- 批准号:
6124630 - 财政年份:1998
- 资助金额:
$ 21.94万 - 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
- 批准号:
6329037 - 财政年份:1998
- 资助金额:
$ 21.94万 - 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
- 批准号:
2747737 - 财政年份:1998
- 资助金额:
$ 21.94万 - 项目类别:
POLYMORPHIC METABOLISM OF ANTINEOPLASTICS IN CHILDREN
儿童抗肿瘤药物的多态性代谢
- 批准号:
3459680 - 财政年份:1990
- 资助金额:
$ 21.94万 - 项目类别:
POLYMORPHIC METABOLISM OF ANTINEOPLASTICS IN CHILDREN
儿童抗肿瘤药物的多态性代谢
- 批准号:
3459678 - 财政年份:1990
- 资助金额:
$ 21.94万 - 项目类别: